CEO Paul LaViolette highlighted significant momentum across Pulse Biosciences’ three market development programs, emphasizing early adoption and progress in clinical trials. LaViolette stated, "We are ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful ...

Pepperl+Fuchs introduces the R2000 UHD Laser Scanner. This IP65-rated 2D photoelectric sensor leverages Pulse Ranging Technology (PRT) and a rotating head to deliver quick, precise and high resolution ...

Management expects disposables and full system sales to grow in line with increased procedure acceptance, but notes that many procedures are currently performed under the pilot program or clinical ...